胃癌及其淋巴结转移灶NF-κB的表达与其化疗疗效分析

NF-κB expression in tissue of gastric cancer and metastases lymph node and its chemotherapy

目的:探讨细胞核转录因子(NF-κB)在胃癌及其淋巴结组织中表达的意义及CAPOX方案(卡培他滨+奥沙利铂)联合艾迪治疗胃癌的疗效,为临床治疗提供参考。方法:回顾性分析我院2008年1月～2009年6月收治的80例胃癌患者的临床资料,80例患者随机分为两组,实验组40例,行CAPOX方案(卡培他滨+奥沙利铂)联合艾迪治疗;对照组40例,单行CAPOX方案治疗。随访1～2年,治疗前取胃癌组织、转移淋巴结及正常胃组织,采用免疫组化法检测不同临床病理特征胃癌患者NF-κB的表达,并比较两组患者治疗前、后NF-κB的表达。结果:胃癌组织NF-κB表达与有无淋巴结转移、分化程度、Lauren分型有关(P<0.05),而与肿瘤大小无关(P>0.05)。随访期间组内比较,治疗后实验组、对照组患者NF-κB阳性表达率均低于治疗前,差异有统计学意义(P<0.05);两组间相比,治疗后实验组患者NF-κB阳性表达率低于对照组,差异有统计学意义(P<0.05)。结论:应用CAPOX方案联合艾迪化疗早期治疗胃癌及其淋巴结转移灶,可以显著降低患者NF-κB阳性表达率,有效提高患者的生存质量,可临床推广使用。

Objective： To investigate the expression of nuclear transcription factor（NF-κB） in gastric cancer and lymph node tissues and effectiveness of CAPOX program（capecitabine ＋ oxaliplatin）.Methods： Clinical data of 80 cases of gastric cancer admitted from January 2008 to June 2009 were analyzed retrospectively.They were randomly divided into two groups by half,experimental group with CAPOX program（capecitabine ＋ oxaliplatin） and Eddie treatment,and control group with single CAPOX program.They were followed up for 1-2 years.Before the treatment,gastric cancer tissue,lymph nodes and normal gastric tissue were taken for detection of NF-κB expression by immunohistochemical method,and the expression was compared before and after treatment.Results： NF-κB expression was associated with lymph node metastasis,differentiation,and Lauren type（P〈0.05）,but had nothing to do with the tumor size（P〈0.05）.Follow-up showed after treatment expression of NF-κB was significantly lower than that before treatment in two groups（P〈0.05）.After treatment,expression of NF-κB was significantly lower in experimental group（P〈0.05）.Conclusion： Early treatment with CAPOX program and Eddie chemotherapy can significantly decrease expression of NF-κB and effectively improve patients′ life quality.It is worthy clinical application.